Evidence map›Paper›PMID 40758627›Full record

ArticleHuman vaccines & immunotherapeutics2025

Real-world single-center data analysis of dual immunotherapy in advanced NSCLC: Efficacy, survival, and adverse events.

Tao Luan, Jianqing Hao, Xiaohong Xie, Xinqing Lin, Shuaiying Wang, Baodan Yu, Qingqing Yang, Changchun Wang, Yang Luan, Gang Yang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Tao LuanFaculty of Life science and Technology, Kunming University of Science and Technology, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.
Jianqing HaoNational Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, P.R.China.
Xiaohong XieNational Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, P.R.China.
Xinqing LinNational Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, P.R.China.
Shuaiying WangAnesthesia Surgery Center, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
Baodan YuNational Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, P.R.China.
Qingqing YangNational Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, P.R.China.
Changchun WangAnesthesia Surgery Center, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
Yang LuanFaculty of Life science and Technology, Kunming University of Science and Technology, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.
Gang YangFaculty of Life science and Technology, Kunming University of Science and Technology, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.
Hanxiu LuFaculty of Life science and Technology, Kunming University of Science and Technology, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.
Ping SunFaculty of Life science and Technology, Kunming University of Science and Technology, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.
Yunhui ZhangFaculty of Life science and Technology, Kunming University of Science and Technology, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.
Nanshan ZhongFaculty of Life science and Technology, Kunming University of Science and Technology, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.
Chengzhi ZhouNational Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, P.R.China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We collected 96 patients who received dual immunotherapy between January 2019 and June 2024, in a 1:1:1 ratio based on PD-L1 expression levels of negative (<1%), medium (1% ≤ PD-L1 ≤ 49%), and high (PD-L1 ≥ 50%). This study evaluates the efficacy and safety of dual immunotherapy in patients with advanced NSCLC, stratified by PD-L1 expression levels. Among the 96 patients, the objective response rate (ORR) was 37.5%, disease control rate (DCR) was 67.8%. In the multivariate analysis of PFS, PD-L1 ≥ 50% (HR = 0.40, 95% CI: 0.22-0.74) was identified as a protective factor for PFS, while PS Score ≥ 2 (HR = 2.74, 95% CI: 1.11-6.77) and stage IV tumors (HR = 2.05, 95% CI: 1.02-4.12) were risk factors. In the multivariate analysis of OS, PD-L1 between 1% and 49% (HR = 0.51, 95% CI: 0.28-0.90) and PD-L1 ≥ 50% (HR = 0.31, 95% CI: 0.17-0.57) were protective factors, with no risk factors detected. The incidence of adverse events was 77.1%, with a 34.3% incidence of grade 3-4 immune-related adverse events. And PD-L1 ≥ 50% group adverse events incidence more common, with an overall incidence of 87.5% and a grade 3-4 incidence of 40.6%. Patients with high PD-L1 expression (≥50%) demonstrated improved progression-free survival (PFS, HR = 0.40) and overall survival (OS, HR = 0.31) but experienced a higher incidence of severe adverse events (40.6%).

Indexed as

Carcinoma, Non-Small-Cell LungImmune Checkpoint InhibitorsImmunotherapyLung NeoplasmsAdultAgedAged, 80 and overB7-H1 AntigenFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeB7-H1 AntigenCD274 protein, humanImmune Checkpoint InhibitorsDual immunotherapyimmune-related adverse eventsimmunotherapysurvival periodtreatment efficacy

Identifiers

PMID40758627
PMCPMC12323414

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.